Table 2 Rate of eGFR decline per year for patients who reached clinical end-points and those who remained event-free
All | Died | ESKD | CVE | Any | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yes (n = 400) | No (n = 201) | p | Yes (n = 108) | No (n = 493) | p | Yes (n = 244) | No (n = 357) | p | Yes (n = 469) | No (n = 132) | p | ||||
Median eGFR slopea (ml/min/1.73 m2/year) | (n = 601) −0.9 (−3.0–0.9) | −1.1 (−3.5–1.2) | −0.6 (−2.2–0.8) | 0.09 | −2.0 (−4.6–−0.8) | −0.6 (−2.5–1.4) | <0.0001 | −1.2 (−3.3–0.7) | −0.7 (−2.6–1.5) | 0.02 | −1.0 (−3.4–0.9) | −0.4 (−1.8–0.9) | 0.01 | ||
Died (n = 400) | ESKD (n = 108) | CVE (n = 244) | Any (n = 469) | ||||||||||||
Revascularization status | NR (n = 517) | R (n = 84) | p | NR (n = 347) | R (n = 53) | p | NR (n = 91) | R (n = 17) | p | NR (n = 201) | R (n = 43) | p | NR (n = 397) | R (n = 72) | p |
Median eGFR slopea(ml/min/1.73 m2/year) | −0.8 (−2.6–0.9) | −1.7 (−9.8–−1.7) | 0.3 | −1.0 (−3.2–0.9) | −1.5 (−11.2–7.6) | 0.9 | −2.1 (−4.6–−0.9) | −1.9 (−5.8–3.1) | 0.9 | −1.2 (−3.1–0.3) | 1.4 (−9.3–5.9) | 0.6 | −1.0 (−3.2–0.9) | −1.6 (−9.8–5.8) | 0.8 |